EyePoint, Inc.
EYPTEyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for serious retinal diseases.
Earnings
Next report
Nov 4, 2026 (in 2 months)Segments
By product
Competitors
By market cap
By revenue growth
By net margin
Profile
EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for serious retinal diseases. The company leverages its proprietary Durasert drug delivery technology to provide sustained-release, intraocular treatments that reduce the frequent injection burden associated with standard-of-care therapies. Its lead pipeline candidates target major ocular conditions including wet age-related macular degeneration and diabetic macular edema.
A specialized player in the ophthalmic drug delivery space, utilizing a proven sustained-release technology platform to differentiate from standard-of-care biologics.
FAQ
- What is EyePoint, Inc.'s market cap?
- EyePoint, Inc. (EYPT) has a market capitalization of $297.4M and trades on NASDAQ.
- What is EyePoint, Inc.'s revenue and profitability?
- EyePoint, Inc. generated $2.8M in trailing twelve-month revenue with a net loss of $306.6M, representing a net margin of -10994.7%, with free cash flow of -$271.3M. The latest reported period is Q2 2026.
- Who are EyePoint, Inc.'s competitors?
- EyePoint, Inc.'s key competitors include 4D Molecular Therapeutics, Regeneron Pharmaceuticals, Inc., Kodiak Sciences, Inc., and others. These companies compete in similar markets and product categories.
- Who does EyePoint, Inc. partner with?
- EyePoint, Inc.'s notable partners include Equinox Science, LLC, Betta Pharmaceuticals Co., Ltd., ANI Pharmaceuticals, Inc., and others.
- Where is EyePoint, Inc. headquartered?
- EyePoint, Inc. is headquartered in United States of America and employs approximately 144 people. It has been publicly traded since 2005.
